Plenty of companies have talked about—and even dabbled in—newfangled pricing schemes. But Novartis is about to seriously raise the bar with new cancer-fighter…
Pfizer could have a challenging year on the patent loss front, starting with the generics of its antidepressant Pristiq now hitting the market.
AbbVie’s Richard Gonzalez was already on the list of highest-paid biopharma CEOs for 2015. And in 2016, his total pay rose even higher.
Gilead Sciences has joined a chorus of drugmakers now trying to blame pharmacy benefits managers for rising drug prices.
Thanks to some crafty payer negotiating from GSK, even if Advair generics win approval, it may be a while before they gain serious traction, even if it wins…
Even as orphan drug laws get a new round of scrutiny in Congress, a new report outlines just how much sales for the meds are expected to take off in the…
Mylan and Biocon today won a court ruling that said they may sell their Herceptin biosimilar in India where it was first introduced three years ago.
As incoming GlaxoSmithKline CEO Emma Walmsley gets ready to move into the company’s top spot, shareholders have objections—and they center on her pay package.
Roche got its hoped-for win in a crucial breast cancer trial—at least in principle. The question is how big that win might be.
Valeant is overhauling executive compensation, hoping to get some of its problems under control—and to avoid repeating its troubled history.